← Back to all trials
Not Yet Recruiting
NCT07653581
rhTPO + CsA vs CsA in the Treatment of LR-MDS With Thrombocytopenia
Conditions: Lower-risk Myelodysplastic Syndromes
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE3
Enrollment: 78
Sponsor: Peking Union Medical College Hospital
Summary
This study aims to compare the efficacy and safety of recombinant human thrombopoietin (rhTPO) + cyclosporine (CsA) and CsA monotherapy in the treatment of lower-risk myelodysplastic neoplasms with thrombocytopenia.
Eligibility Criteria
Inclusion Criteria:
1. Age ≥ 18 years old;
2. Confirmed diagnosis of lower-risk MDS;
3. Platelet ≤ 30×109/L, or \< 50×109/L and accompanied by bleeding events;
4. Baseline liver and kidney functions \
Source: ClinicalTrials.gov (NCT07653581). StuddyBuddy aggregates publicly available trial information.
